Reagents that block the PD-1/PD-L1 interaction, e.g. anti-PD-1 and anti-PD-L1 antibodies, induce an anti-tumour response via the reinvigoration and expansion of CD8+ cell populations and by increasing their cytotoxic activity [35]. Here, CD8A is linked to neoplasm.